0.09% Medicare Advantage Rate Hike Sparks 14% Drop in CVS Health Stock
On January 27, the Centers for Medicare & Medicaid Services proposed only a 0.09% increase to 2027 Medicare Advantage rates, far below analysts’ 4–6% forecasts, triggering a 14% drop in CVS shares that session. Bank of America cut its CVS price target from $100 to $95 while maintaining a buy rating, contributing to a premarket gap down to $75.39 on heavy 11.9 million share volume.
1. Market Performance and Recent Volatility
CVS Health shares rallied by 2.82% on the most recent trading day, closing at a level that reflected renewed investor optimism after broader market weakness. That rebound followed a 14% sell-off on January 27 when the Centers for Medicare & Medicaid Services proposed a 0.09% rate increase for Medicare Advantage plans in 2027, well below investor expectations of 4%–6%. Earlier in the week, shares also gapped down at the open after Bank of America lowered its price target from $100 to $95 while maintaining a buy rating, triggering high-volume trading of nearly 12 million shares during the session.
2. Analyst Ratings and Price Targets
A total of 24 sell-side analysts cover the stock, with 20 maintaining buy ratings and four recommending hold. The consensus price target stands at $94.86. Recent notable revisions include Sanford C. Bernstein’s market perform rating with a $91 target, TD Cowen’s upgrade to buy with a $105 target, Evercore ISI’s outperform rating with a $95 target and Barclays’ overweight rating with a $93 target.
3. Financial Fundamentals and Guidance
In its latest fiscal quarter, CVS Health reported revenue of $102.87 billion, exceeding the consensus estimate of $98.85 billion by 4.1%, and delivered earnings per share of $1.60, beating the $1.36 forecast by 17.6%. The company set full-year 2025 earnings guidance in a range of $6.55 to $6.65 per share, reinforcing its longer-term growth trajectory despite recent market headwinds. Management highlighted a 7.8% year-over-year revenue increase and a net margin of 0.12% for the quarter.
4. Institutional Holdings and Dividend Policy
Institutional investors own more than 80% of CVS Health’s outstanding shares. Vanguard Group increased its stake by 1.7% to 120.4 million shares (valued at approximately $8.3 billion), while Capital World Investors grew its position by 2.1% to 68.4 million shares. Other major holders include State Street Corp with 58.9 million shares and Geode Capital Management with 28.6 million shares. The company declared a quarterly dividend of $0.665 per share, representing a 3.7% annualized yield and a dividend payout ratio of 700%, payable to shareholders of record on January 22.